


Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures

Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology

Advent France Biotechnology launches its second fund with a first close at €86M ($102M)

New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies
